Tags : Regimen

Biosimilars Clinical Trials

Celltrion Report Results of Truxima (biosimilar, rituximab) Based Regimen in

Shots: Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m2) + lenalidomide (20mg, day 1-21, qd) + acalabrutinib (100mg, day 1-28, bid) (R2A) is well-tolerated and effective in relapsed/refractory aggressive B-cell lymphoma In the 13 patients who underwent disease assessment following the R2A regimen, ORR (69%) and CR (31%), […]Read More

Regulatory

Merck Receives EU’s CHMP Positive Opinion for its Zerbaxa (ceftolozane

Shots: The positive CHMP opinion of Zerbaxa (3gm) is based on P-III ASPECT-NP study assessing Zerbaxa in patients with hospital-acquired pneumonia including ventilator-associated pneumonia. The EC will review CHMP’s opinion to grant centralized marketing authorization to the combination therapy The CHMP positive opinion of Keytruda + Inlyta is based on P-III KEYNOTE 426 study which […]Read More